Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma

Richard Kefford(Broad Institute), Adil Daud(University of California, San Francisco), Patrick Chun(University of Michigan), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Jeffrey S. Weber(NYU Langone Health), Peter Hersey(The University of Sydney), X. Li, Amita Patnaik(South Texas Accelerated Research Therapeutics), Kevin Gergich(Merck & Co., Inc., Rahway, NJ, USA (United States)), W. Hwu, F. Stephen Hodi(Harvard University), Anthony M. Joshua(St Vincent's Hospital Sydney), Caroline Robert(Institut Gustave Roussy), Tara C. Gangadhar(University of Pennsylvania), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jedd D. Wolchock(Memorial Sloan Kettering Cancer Center), A. Ribas, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))

Unknown

September 19, 2014

Cited by 0

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|Science|2017|6.6k

|New England Journal of Medicine|2015|5.9k

Related Papers